Skip to main content
. 2021 Jan 14;11:609689. doi: 10.3389/fimmu.2020.609689

Figure 3.

Figure 3

CG-598 mitigates DNBS-induced colitis in a dose-dependent manner. Mice were administered intra-rectally with 3% DNBS (n=9 or 10 per group). Three different doses of CG-598 or vehicle formulation were orally administered once a day. (A) Body weights. Two-way ANOVA. ***p < 0.001, compared to the vehicle group. (B) Colon lengths at day 4. One-way ANOVA. ns; not significant, *p < 0.05, **p < 0.01. (C) Representative colon histology from each group (×200 magnification). Black arrows mark severely inflamed regions. (D) Histological score. Data are representative of three independent experiments. One-way ANOVA. Data are shown as mean ± SEM, ns, not significant.